IBB — iShares Biotechnology ETF
Data updated: 2026-08-25
IBB — iShares Biotechnology ETF. United States Multi-Cap / All-Cap Blend / Core Health Care Equity · $9.09B AUM. Holdings, fees, performance and SEC filings.
IBB Fund Overview
IBB — iShares Biotechnology ETF is a US ETF managed by iSHARES TRUST, categorised as United States Multi-Cap / All-Cap Blend / Core Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: iSHARES TRUST
- Category: United States Multi-Cap / All-Cap Blend / Core Health Care Equity
- Assets under management: $9.09B
- 1-year return: 50.6%
- Ticker: IBB
- SEC CIK: 0001100663
- SEC series ID: S000004350
- Share class ID: C000012080
IBB Holdings
Top 10 holdings of iShares Biotechnology ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| BlackRock Funds III | 11.66% |
| Vertex Pharmaceuticals, Inc. | 8.08% |
| Amgen, Inc. | 7.83% |
| Gilead Sciences, Inc. | 6.84% |
| Regeneron Pharmaceuticals, Inc. | 4.91% |
| Argenx SE | 3.76% |
| Alnylam Pharmaceuticals, Inc. | 3.12% |
| Natera, Inc. | 2.89% |
| Revolution Medicines, Inc. | 2.78% |
| Biogen, Inc. | 2.47% |
IBB Portfolio Allocation
Asset-class allocation of iShares Biotechnology ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.9% |
| Cash & Equivalents | 12.0% |
IBB Performance
Total returns for IBB (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 12.7% |
| 1 year | 50.6% |
| 3 years (annualised) | 14.7% |
| 5 years (annualised) | 3.3% |
IBB Risk Information
Risk metrics for IBB, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 16.1%
IBB Costs and Fees
IBB costs about $44 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.44%
- Gross expense ratio: 0.44%
- Portfolio turnover: 18%
- Brokerage commissions: 0.92 bps of average net assets (SEC N-CEN)
IBB Cashflows
Over the 12 months to 2026-06, iShares Biotechnology ETF had net inflows of $1.04B, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-06 | $299.23M |
| 2026-05 | −$175.17M |
| 2026-04 | −$166.73M |
| 2026-03 | −$331.98M |
| 2026-02 | $102.14M |
| 2026-01 | $21.34M |
IBB Debt Constituents
No individual debt constituents are reported in iShares Biotechnology ETF's latest SEC N-PORT filing.
IBB Prospectus and SEC Filings
Official iShares Biotechnology ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2025-07-22
- Prospectus (485BPOS) — filed 2024-07-19
- Prospectus supplement (497) — filed 2023-11-20
- Portfolio holdings (N-PORT) — filed 2026-08-25
- Portfolio holdings (N-PORT) — filed 2026-05-28
- Portfolio holdings (N-PORT) — filed 2026-02-25
- Annual census (N-CEN) — filed 2026-06-15
- Annual census (N-CEN) — filed 2025-06-13
Related Funds
Other United States Multi-Cap / All-Cap Blend / Core Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.